Company news: Dendreon and CPPIB Credit Investments

Dendreon agreed to sell its royalty interest in Victrelis (boceprevir) for $125 million in cash, the company said. The firm did not disclose the exact royalty rate. The royalty interest was acquired by CPPIB Credit Investments, a wholly-owned subsidiary of CPP Investment Board, and the transaction is expected to close this month. ISI Group analyst Mark Schoenebaum estimated peak global Victrelis sales of $970.5 million in 2014. All-oral therapies, such as Gilead/Pharmassset's PSI-7977 could reach market in 2015 and are expected to impact currently marketed HCV drugs like Merck/Roche's Victrelis.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.